2.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
Can Tango's Synthetic Lethality Approach Transform Cancer Treatment? Key Conferences to Watch - StockTitan
Tango Therapeutics executive sells shares worth $43,865 - MSN
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Declines By 22.5% - MarketBeat
Analysts Offer Predictions for TNGX Q3 Earnings - MarketBeat
Q1 Earnings Forecast for TNGX Issued By Leerink Partnrs - MarketBeat
Q3 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares - MarketBeat
Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance
What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Tango Therapeutics CFO Beckman sells $25,281 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Australia
Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com Australia
Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN
Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News
TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle
Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha
TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times
Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
Cantor Fitzgerald Estimates TNGX FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts TNGX FY2025 Earnings - MarketBeat
Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St
Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks
Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat
Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):